Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Actually the post was in response to something that was mentioned concerning a grant-amount, and my concern of IPIX being viewed as an ‘equal manager’ of said-funds (amount too) in similar application and circumstance (to Moderna)
ZERO question concerning Moderna’s pipeline etc.
Grant-worthiness and how criteria are met (or not) and ability to execute... are likely considerations given the circumstances.
This was my point. Plain and simple.
This isn’t personal. This is my MBA-mind assessing ‘fitness to execute’ during a time of crisis.
Some on here seem to think with emotional attachments to their investments here.
The Pharma Lobby doesn’t give 2 schitts about any emotional attachment to IPIX. They care about lining their pockets. Have you ever heard of or seen the IPIX Lobby? How much pull do you think we have with the current administration?
This is sort of my point. If we don’t have those resources, then we sure as hell better have a world-beating strategy and execution.
Yes the RBL’s are helping. To what-end i suppose we’ll learn in the coming months.
A reminder: Leo didn’t ‘put B in the spotlight with the RBL’s’... they came to him looking for a Mimetic. He just supplied the samples. I wouldn’t reference it as a ‘stroke of genius’ as much as just replying to an email...
Further... this has nothing to do with ‘what makes a company great in my eyes’... Not saying anything about making companies great... My initial post concerning Moderna and the grant, specifically related to ‘grant-worthiness’ in the eyes of the Grantor.
helpful?
(And yes, I’d hope we hire the necessary staff and/or sell/license indications and get the hell on with our lives here... )
Not so sure Moderna is a great comparison?
Moderna is an actual company run by people with actual backgrounds growing businesses and executing on critical strategy. They're funded. They have R&D capabilities. They also have credibility.
Ipix essentially is Leo.
Do you know who Leo is?
This is who Leo is:
Yes.
Would you not consider a grant, either government provided or private in nature, to be a valid source of funding? (Among others?)
Increased credibility.
Global Pandemic relevance with Brilacidin
RBL tests showing efficacy behind us with more on the way.
RBL grant applications filed.
Please don't be obtuse.
You know what I'd love to see?
...since we're kicking stuff around here related to IPIX trajectory:
As capital-raising should theoretically be easier for Leo these days, why wouldn't he raise enough cash however he could (private raise might not be the worst) to run his own small human trial in partnership with a hospital (or 20), and then take the findings to the FDA for a BTD and even IND application?
Skip the BP approach for partnership, and simultaneously take whatever grant funds he could get (assuming not-stipulated) to help facilitate an uplist (after filling out the remaining requirements of course), and then take a bath in the institutional investment cash he'd be awash in following the potentially positive human trial results?
Then build out your network for distribution while you're running the trials, or negotiate a wholesale agreement to unload the first round to the government for their stockpile.
Not understanding why people keep comparing IPIX to CYDY?
We're literally nothing alike... Look at their balance sheet and fundamentals compared to ours.
https://www.otcmarkets.com/stock/CYDY/financials
Understanding what happens when a business is capitalized is sort of critical to understanding what its capabilities look like related to product development opportunities and strategy.
IPIX has and has-had close to zero cash, and therefore a demonstrated inability to progress the pipeline. Plain and simple.
Investor confidence has been eroded over time due to this demonstrated inability to progress the pipeline and/or form meaningful partnerships to progress the science. This is further exascerbated by constant hype-PR's that lead to minimal/zero action.
CYDY has the appearance of a legitimate company. They have a mostly-full C-Suite, along with a populated BOD. 20 Employees, 5 different 'Investor Relations' entities listed, etc.
IPIX is structured more like a holding company with Leo and Jane being the only listed employees.
We get bits and pieces in PR's and 'Corporate Reviews' concerning the 'hopes and dreams' of the business direction, but never any financial strategy to power the dreams.
Make no mistake... I'm a Long and will continue to be until I can realize some return on my investment. I'm here for the science. What I hadn't counted on was management lacking the ability to partner or fund the business adequately to wield an effective strategy to forge a path to drug-commercialization.
I see potential moving forward, but time hasn't been and isn't on our side. Things need to happen significantly faster than they do in Leo's world.
There's a Pandemic raging and thousands are dying... daily. Why would the potential 'Gold Standard of Treatment' be locked-away in grandpa's medicine cabinet collecting dust, when it could be out there saving lives?
Hoping we get funded sooner than later. This is beyond ridiculous and embarrassing.
Partnership could be in many different forms.
We could benefit greatly from a hospital network provider partnership to run clinical trials at no-cost to us.
We could benefit from a manufacturing partner to alleviate the economic burden on our share-dilution.
We could benefit from a sales/distribution partner pending positive human trial results.
Etc etc etc.
I’m not just thinking ‘BIG partnerships’ with a BP or otherwise... but any/all along the way depending on structure could prove beneficial. Sometimes it’s ALL about the strategic partnerships when you have nothing. No, we don’t want to ‘give anything away’, but together we could certainly be stronger than LeoPharma is currently...
Did we need yet another reason to have B further tested by RBL's for additional Corona indications?
https://www.bbc.com/news/health-53218704
This is getting out of hand...
This is awesome. Thank you so much for sharing this!
Not sure I agree.
Pandemic situations don't present themselves with regularity.
Capitalizing on government funding doesn't happen with a Pandemic behind it often either.
This is the 'perfect storm' and we happen to be at the right place at the right time with B.
Cost to move things from where we are currently is relatively minimal (compared to B-IBD etc). Contracting assistance and leverage at this point isn't as difficult to manage as possibly at other times either, due to COVID and our current test results.
Further, leveraging a CRO, Government assistance for both funding and distribution etc, would likely see revenue north of $1B just with CONUS distribution, ROW notwithstanding.
My thought is: the quick-and-dirty could be incredibly shortsighted, given the context.
I'm all for seeing cash.. lord knows I'm sick of the hold-down... but the further this can be progressed 'organically', the better the longer-term valuation looks. Why not leverage 'free money' from the government and avoid partnership if possible?
Except this: '...suspended AOI 9.5 Pre-exposure and post-exposure prophylaxis'
Possibly concerning, given B's MOA...?
Could also be with a CRO, grant money, the RBL's, and using FDA guidance for framework with a CRO.
Partner takes a BIG %, but the upfront $ would be helpful for us short-term for sure.
I think with a CRO and smaller P2, Leo could do it 'in-house' and retain revenue possibly...
-stairstep to an M&A down the line.
Here's another decent article to back that up; supporting room for B in the market:
https://www.fiercepharma.com/pharma/roche-s-actemra-fails-italian-study-early-stage-covid-19-pneumonia?mkt_tok=eyJpIjoiT1dVMlptSTNPVFZoWlRNeiIsInQiOiJmOW9ZVk9RMG14YmFlZjNYZEd1NVdHOHI3RGlcL0pJb1wvUkxuODFSY01YV3JPc2xRKzNKeTBza205ZmpRTm5oUitsY3RUWWxtTEdHcnNoSUJnaWVTSTZjZnZsWHgwNWNTSklXSWlcL1loXC9WSENnOUhwQmU0R0VaVlFTQ3JYRUpUOVUwUHlZVXdmRkZ6UGd3aklLMnhNVStnPT0ifQ%3D%3D&mrkid=74197490
Roche's Actemra falls short in Italian study in early-stage COVID-19 pneumonia
It's actually not a distraction as much as it's quite literally our 'financing reality'.
50M shares available to the MFO (give or take) to dilute any buying, is considerable.
I'm not discounting today's news in the slightest... I'm just acknowledging our grim financial reality.
A grant and/or partnership will change everything, quite literally in the blink of an eye. Until then, the MFO is our reality, however.
(Sort of like living off credit cards with no income, and carrying a super-high balance. You're committed to predatory interest rates-of-destruction + principal owed.)
I disagree. It's not making assumptions concerning the mental capacity of the MFO whatsoever.
It's accounting for Leo's cash-demands to manufacture drug so we have a suitable supply for human clinical trials.
We had sachets for B-OM on hand, but not IV. This requires cash.
Where else would it possibly come from?
MFO is my belief.
I believe them to have the option to access around 50M shares (maybe slightly less now) to unload into any price movement. If they can keep SP under $.25 then they keep Leo from accessing the Aspire agreement (if memory serves), so it's in their interest to remain the sold financier of IPIX as long as possible... I think.
I believe our best-case is to receive grant-based funding (or partnership) and to have the cash-transfer to reflect organically on the balance sheet to gap us up and away from the MFO's toxic financing grip.
'The Incredible Hulk' ?
With respect to a 'sponsor', if it's someone vertical and onshore... they could help a ton with logistics and manufacturing.
Leo isn't a BP. He has a staff of Jane, a book-keeper and several contractors. Rolling out a multi-national series of clinical trials understaffed isn't a reality.
A B-OM deal now would be timely. Our fundamentals are our biggest concern.
Having a floor in place would allow for a myriad of things to transpire.
Currently, options are severely limited (as have been for the years I've been invested here).
I would dearly like to see SOME revenue realized sooner-than-later, so the science can progress.
Good science dies at the hands of bad management.
I'm hoping we emerge someday soon, from the cloud hanging over the company and are able to realize progress.
Someone a few days ago mentioned 'guidance' related to trial-structure for C-19 drugs.
This was out this morning on Endpoints, in case folks missed it.
I think there's been some question concerning trial-design and C-19 and how IPIX (Leo, the 1-man-band), can execute on Brilacidin moving forward.
It's surprising to many, how much can be accomplished once the proverbial money-cannon is loaded and can be fired at problems at-will. Grants, pending positive tests by RBL's, should theoretically enable Leo to hire/contract personnel to assist with whatever needs to be accomplished to move things forward.
I'm not sure what a 'partnership' would look like, but given the track-record to-date with IPIX, I would think a partnership would present more of a liability to a BP than an M&A of some sort (or exclusive global-license for indication). The value is in the IP. Given grant-money IPIX would theoretically be able to leverage government resources and hire as-needed. Not the solution some may be looking for, but in lieu of a colossal offer from a BP, I'm guessing this is the option Leo is examining closely.
Endpoints-
I'm 100% NOT arguing with the potential of the existing pipeline.
Please do not misunderstand my concerns here.
Prurisol has exactly nothing to do with the forward-direction of the business model.
Period, end of story.
For folks to continue to drag it out of the ground and parade it about is nothing short of spreading false-hope and fiction. It's a purely fictional narrative.
Additionally: we don't know if AbbVie, Pfizer, J&J, Roche... et.al are on-deck or not.
I think it's up to Leo to navigate these current waters.
I'm praying for a miracle here, along with most of the rest of us Longs.
Hoping also for a deal from LW in the OM department. It's getting fairly long in the tooth, as it were...
Next week could bring results to catapult us in the direction we so desperately need also (obviously).
Folks here keep moaning about us 'needing trading volume' etc.
We're not 'volume victims'...to the extent that some are indicating, and to suggest as much is to misunderstand how fundamentals directly affect MC.
Our current SP will literally change overnight if/when our fundamentals change.
The only way that happens is on account of either a deal or a grant or an M&A.
We're not in a position to uplist, so another exchange isn't possible. (board, audit etc).
Are you scared of the truth?
P is dead.
Why continue to foment nonsense when it's literally got nothing to do with current company direction?
It's not even a remote-option.
https://pubchem.ncbi.nlm.nih.gov/substance/393797289
https://pubchem.ncbi.nlm.nih.gov/substance/393797289#section=Related-Compounds
Not sure why folks are still talking about Prurisol on here?
Leo gave up the patent and it’s long gone.
Prurisol is dead (to my knowledge) and the company isn’t looking back.
To continue to discuss the ‘merits of Prurisol’, imo, is to misunderstand the current state of ‘development’
related to IPIX and their current patent inventory.
It was based on Docking and Quantum Mechanical Scoring.
No lab-tests were run. This was a computer-run based on molecular structure of compounds, screened for suitability.
Billions of times faster and more effective than taking them to the lab.
Entering that number, I get no reference to anything 'rejection' related (or anything for that matter)
From the USPTO under 'Patent Application' or 'Patent info'.
I've tried numerous searches.
Can you detail where you located a 'Final Rejection' document please?
Thought that was related to BioNTech https://biontech.de/
not IPIX.
My understanding of the LW engagement precludes anything outside of B-OM.
NOT counting on them to have anything to do with this particular indication.
There's plenty of gov't $ and visibility w/o them in the space.
My concern is: Leo's ability to negotiate something meaningful in deeply-complicated discussions.
(see: $400k AS deal...)
But remember, BARDA etc on the Gov't side, along with BP coming to us in this instance, are the differences from the B-OM situation.
Dire global need vs. theoretical 'Blue Sky' market opportunity.
...or what if they didn't have the drug to ship?
Are you aware, with a confirmation, that materials were even submitted to 'the second MTA university' for testing?
Very interesting...
...but no specifics. Guessing if there are details, they're unable to disclose currently.
Dr. David Ho is considered an expert in this field.
Give this segment a watch.
It's informative and helpful I think, and might help to shed some light on what's happening here and why IPIX and Brilicidin could be more relevant than other candidates, possibly.
https://www.msnbc.com/rachel-maddow/watch/straight-talk-on-the-search-for-a-coronavirus-cure-81005125933
My feeling is that we need both.
IV and aerosol in the instance of CV-related cases would be critical-care team administered and monitored... this is an ICU situation, not as someone else mentioned, a tennis-court scenario in the hands of the 'random public'.
A respiratory professional should be well-enough equipped to monitor dosing.
A point of note: Trump is not a medical professional. He's not even really a 'business professional' with any capability. I remain unconvinced that anything he says in this situation related to accurate numbers/info about much of anything, can be taken seriously.
On the ground here (I'm in Colorado) much of the critical management concerns are being handled locally and regionally. We have little/no federal assistance, so local hospitals are fending for themselves. So far nothing that 'Trump has done' has meant anything to our situation (or others I'm aware of).
Aerosol is the same treatment consideration here as it would be for asthma.
Inhalers are dosed.
It can't really get much easier than using an inhaler, honestly.
...smart move shaking their hands and giving them all the Coronavirus...
Pretty unbelievable.
Talking about a highly contageous ID; having been in close proximity to others who've recently tested positive, and then he holds a presser like this.
Unreal.
Buyout could be in the consideration-set, I'd imagine...
...however, I'd be inclined to think it'd be significantly north of the $800M you mentioned.
There are several multi $B indications in there, before getting to the COVID scenario.
I guess we'll see how she goes...
I don't know what he's up to strategy-wise...
But it (IPIX) seems to currently resemble a holding company in structure and by its movements.
Leo's sitting on IP. Zero development capability in-house.
Brilicidin and Kevetrin are what's left, and neither seem to be able to advance further without partnership or cash (or a combination).
I don't know if Leo views it as too much of an unnecessary hassle to try to meet NASDAQ requirements to uplist, when he can theoretically partner/license B-IBD, B-OM, and now possibly B for COVID-19, to get things moving.
Once a meaningful deal is complete, the tox-work for Kevetrin will likely be completed, and the other indications can be partnered (hopefully), and then away we go.
The other thing I was wondering is: Since there's been attention related to the B-IBD oral P1 from BP's most likely, what happens following a successful B-COVID-19 outcome?
I would sort of wonder if this would completely validate the platform (Brilicidin) for a BP to make a move to acquire (B or IPIX in total).
We know J&J was interested in using it (Bril) for biofilm applications, but it needed to have an FDA internal-approval (I believe this to be the case)... SO pending approval of some sort related to COVID... what would that opportunity (and others) look like?
We need something to drop, at this point. Not another 'just a few more months', or 'another proof-of-concept-trial'... we need something real.
The B-OM partnership would be a good place to start, in addition to hopefully favourable COVID-19 results.
Fingers crossed for the miracle that we've been waiting ages for...
I think we're a LONG way off, sadly...
...but yes you're identifying some of the basic requirements. Apparently there may be some room for 'interpretation' in some instances (I've heard).
Given our current structure, I'm not even sure it's on Leo's radar.
We've got some hiring to do, a BOD restructure, not to mention the financial concerns.
(for starters, that $4sp requirement would equal an approx $1B MC for IPIX, given current OS count)
I'd wonder if in the shorter-term if it's just easier for them to pen this apparently ridiculously elusive B-OM deal, realize revenue from an upfront payment, see what happens with the stock... Possibly hire a CMO, and then see what comes of this COVID-19 nightmare.
Lots of things happening currently, and I believe it really only takes one as a catalyst to change literally everything, in IPIX-land.
Until then sadly, uplisting is just fantasy-land.
I saw it. One of the first things I saw this morning, actually.
IF something amazing happens, then of course it's great!
I'd love to see SOMETHING from us reach the proverbial light-of-day.
I'm a Long, and got into this a handful of years back because I believed in the science behind the relentless PR's. With each progressive hype-PR with a corresponding milestone, I'd bought more shares, to the current tune of being -79.5% basis overall, and I know I'm not the worst-case out there either.
What I hadn't counted on were endless proofs-of-concept, questionably-designed or microscopic-trials of statistic insignificance (to anyone other than IPIX), and an endless lack of cash to fuel these colossal stretches of time-space-nothingness.
Businesses in this sector burn cash.
Leo's inability to fund the company properly isn't exactly assisting us with any SP-traction currently, despite all-time volume these last several days, thanks to COVID-19.
Let's pray for a miracle-assist from the government here and that B gets to actually help some folks in need.
Sitting around for another 12yrs while Leo tries to figure out how to make more 'progress' without funding would be too painful.
'Hoping/expecting/anticipating partnership' isn't going to get us further, alas. We need something to actually happen (and not just a partnership with $400k to fund Leo personally, with little-else, for a company that has a demonstrated burn-rate of not-less than $3M/yr)
Wondering if we're going to actually get any update on whether the product shipped or not?
IF the clock started running with the RBL on the 27 Feb, then this week would we have an update, based on the language used from the PR they provided?
Did Leo / CoreRX / etc have raw product on-hand to actually ship?
We never learned.
Was material actually shipped?
We never learned this either.
I'm with others who feel like more specific info would be beneficial in this situation.
The now-standard 'IPIX hopes/expects-to/plans/etc' doesn't mean anything with real timelines, when actual human lives are on the line...
...Do you think Leo is driving about with samples of B in his glovebox?
My guess is one of their 2 disclosed manufacturers would ship directly?
It's not like IPIX and their new virtual-office has a secure storage facility for fresh product.
C'mon man.